Author:
Bueno CBF,Trarbach EB,Bronstein MD,Glezer A
Funder
Fundação de Amparo à Pesquisa do Estado de São Paulo
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Reference41 articles.
1. Hardy J (1973) Transphenoidal surgery of hypersecretiom pituitary tumors. In: Kohler PO, Ross GT (eds). Int Congr Ser 303. Amsterdam, pp 179–194
2. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B et al (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84(7):2518–2522
3. Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G et al (1997) Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82(11):3574–3579
4. Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R et al (2000) Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 85(6):2247–2252
5. Filopanti M, Barbieri AM, Angioni AR, Colao A, Gasco V, Grottoli S et al (2008) Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas. Pharmacogen J 8(5):357–363
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献